Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

RCT (n=500) reports subcutaneous fixed-dose combination of pertuzumab+trastuzumab provides non-inferior cycle 7 pertuzumab serum C trough concentrations to intravenous pertuzumab+trastuzumab in the neoadjuvant setting with comparable total pathological complete response rates.

Source:

The Lancet Oncology